FDA Compliance & Off-Label Promotion — Biotech Scenario
A Physician Asks a Sales Rep About Using Your Drug for an Unapproved Condition. The Rep Knows the Trial Data Looks Promising. Can They Share It?
A real biotech and pharma compliance scenario — with three decision options and the right answer.
Quick Answer
Can a pharmaceutical sales representative share clinical trial data about unapproved uses of a drug with a physician who asks? No — this is off-label promotion, one of the most prosecuted areas of pharmaceutical compliance, regardless of who initiated the conversation, how accurate the data is, or how patient-focused the physician’s intent seems. This scenario shows why the existence of clinical trial data does not create permission to promote it, and why Medical Affairs — not Sales — is the compliant channel for these conversations.
The Situation
A pharmaceutical sales representative is calling on an oncologist who prescribes your company’s approved therapy for a specific cancer indication. During the visit, the physician asks whether your drug might be effective for a related cancer type where there is currently no approved standard of care. The physician says they have patients who are running out of options. The rep knows that your company is conducting a Phase 2 trial for exactly this indication, that the early efficacy data looks very promising, and that the physician is genuinely trying to help patients. The rep considers sharing the trial data informally as “scientific background.”
What Should the Rep Do?
Choice A Share the trial data informally as scientific background. The physician asked — this isn’t a promotional pitch. The data is factual, the intent is patient-focused, and the physician will likely find it through a medical database anyway. Helping a physician understand the emerging evidence isn’t the same as promoting an unapproved use.
Choice B Decline to discuss unapproved uses and offer to connect the physician with Medical Affairs, who can engage in a compliant scientific exchange about the ongoing trial and available data in an appropriate context.
Choice C Mention that there is an ongoing trial without discussing the data or outcomes. This way, the physician knows something is coming without the rep technically crossing the line into promoting an unapproved use.
The Right Call
Choice B — Decline and refer to Medical Affairs.
Off-label promotion is one of the most heavily enforced areas of pharmaceutical compliance. The physician’s intent, the rep’s intent, the accuracy of the data, and who initiated the conversation are all irrelevant to whether the conduct constitutes off-label promotion. Medical Affairs exists specifically to handle physician inquiries about unapproved uses in a scientifically rigorous and legally compliant context. That function is not a formality — it is a compliance firewall that protects both the physician and the company.
Why This Scenario Is Harder Than It Looks
The physician asked — so it feels like information, not promotion.
Off-label promotion law does not hinge on who initiates the conversation. A sales representative who responds to an unsolicited physician question with data on an unapproved use is engaging in off-label promotion, regardless of the direction the conversation took. The rep’s role, the context of the visit, and the commercial nature of the relationship determine compliance — not the question asked.
Patient need does not create regulatory permission.
The physician has patients who are running out of options. That is a genuine and compelling clinical situation. It does not change the regulatory analysis. FDA approval exists to protect patients from treatments whose safety and efficacy have not been established in controlled conditions — and the pathway to establishing that evidence is through clinical trials, not through informal data sharing between sales reps and physicians.
Choice C is not a safe middle ground — it is still off-label promotion.
Telling a physician that an ongoing trial exists for the indication they asked about — without disclosing outcomes — is still communicating information about an unapproved use in a commercial context. The FDA has cited similar “trial seeding” conversations as off-label promotion. There is no compliant version of this conversation that a sales rep can have. The compliant version requires Medical Affairs.
Frequently Asked Questions
What is off-label promotion and why is it illegal?
Off-label promotion is the marketing or promotion of an FDA-approved drug for a use, dosage, patient population, or indication that has not been approved by the FDA. It is illegal under the Federal Food, Drug, and Cosmetic Act because the safety and efficacy of the drug for the unapproved use has not been established through the controlled review process that FDA approval requires. Pharmaceutical companies have paid billions in settlements for off-label promotion violations.
Can a physician prescribe a drug off-label?
Yes — physicians have the legal authority to prescribe approved drugs for off-label uses based on their clinical judgment. The restriction applies to manufacturers and their representatives promoting the drug for those uses. A pharmaceutical company cannot market or promote off-label use, but a physician can prescribe it. This distinction is the line that sales representatives must not cross.
What can Medical Affairs do that Sales cannot in this situation?
Medical Science Liaisons (MSLs) in Medical Affairs can engage in compliant scientific exchange with physicians about ongoing clinical trials, emerging data, and unapproved uses — but only in a non-promotional context, with appropriate scientific disclosures, and following specific compliance protocols. This conversation is appropriate because MSLs are not part of the commercial sales function and are held to a different standard. Referring the physician to Medical Affairs is not a deflection — it is directing them to the person who can actually help them compliantly.
What are the consequences for a pharmaceutical company found to have engaged in off-label promotion?
Consequences have included billions of dollars in Department of Justice settlements, corporate integrity agreements with ongoing compliance monitoring, individual criminal charges against executives and sales managers, exclusion from federal healthcare programs (Medicare and Medicaid), and significant reputational damage. Off-label promotion enforcement is one of the most active areas of pharmaceutical compliance investigation.
How should a sales rep respond when a physician asks about an off-label use?
The compliant response is to acknowledge the question, explain that you can only discuss approved indications in your sales role, and offer to connect the physician with Medical Affairs or a Medical Science Liaison who can engage in a scientific exchange. This response is not a refusal to help — it directs the physician to the resource that can help them properly and compliantly.
How to Use This Scenario in Training
FDA compliance and Code of Conduct training establishes the policy. This scenario makes it stick.
This scenario is essential for pharmaceutical and biotech sales representatives, district managers, and anyone who interacts with prescribing physicians. The “physician asked first” framing is the most common rationalization in off-label promotion cases — employees who have practiced recognizing it as a compliance trigger are better protected when a real situation arises.
More Compliance Scenarios
|
Regulatory Integrity Commercial pressure to submit a drug before safety studies are complete. What do you do? |
Anti-Kickback A physician is paid to speak at 14 events, and their prescription volume surged. Is that a red flag? |
Anti-Corruption A distributor says you need to pay a vague consulting fee before the government contract can close. |
Compliance Training Built for Biotech and Pharma
Xcelus develops scenario-based compliance training for pharmaceutical and biotech organizations — including off-label promotion, anti-kickback, regulatory integrity, and research ethics scenarios built for the specific risk areas your sales and medical teams face.